Fundraising FoxMinutia
4 known investors
Find your way into Minutia
Sign up to see every warm intro you have to Minutia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Minutia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.
Investors · 4
Demos Strategic Investing Partnerslisted by Demos Strategic Investing Partners
How we know: Demos Strategic Investing Partners's portfolio page · Not right? Tell us
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $870K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Minutia do?
- Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.
- Who are Minutia's investors?
- Minutia's investors include BioBrit, Demos Strategic Investing Partners, Lucas Venture Group, SOSV.